Silybin and metabolic disorders
IM - COMMENTARY
- 45 Downloads
Mediterranean diet represents a fundamental strategy in the prevention of cardiovascular and metabolic disorders as demonstrated by observational and interventional trials [ 1]. Among the most represented elements of the Mediterranean diet are polyphenols that display protective effects on cardiometabolic disorders by counteracting oxidative stress that represent a key point of the preventive strategy in this setting. Hence, oxidative stress seems to be involved in both cardiovascular and metabolic disorders [ 2]. Indeed, atherosclerotic disease is associated with increased level of oxidative stress [ 3] as well as metabolic disorders such as non-alcoholic fatty liver disease (NAFLD) [ 4] and diabetes [ 5] (Fig. 1).
Compliance with ethical standards
Conflict of interest
The authors declare that they have no conflict of interest.
Statement on human and animal rights
This article does not contain any studies with human participants or animals performed by any of the authors.
- 3.Violi F, Pignatelli P, Pignata C, Plebani A, Rossi P, Sanguigni V, Carnevale R, Soresina A, Finocchi A, Cirillo E, Catasca E, Angelico F, Loffredo L (2013) Reduced atherosclerotic burden in subjects with genetically determined low oxidative stress. Arterioscler Thromb Vasc Biol 33(2):406–412. https://doi.org/10.1161/ATVBAHA.112.300438 CrossRefGoogle Scholar
- 5.Santilli F, Lapenna D, La Barba S, Davi G (2015) Oxidative stress-related mechanisms affecting response to aspirin in diabetes mellitus. Free Radical Biol Med 80:101–110. https://doi.org/10.1016/j.freeradbiomed.2014.12.010 CrossRefGoogle Scholar
- 8.Trouillas P, Marsal P, Svobodova A, Vostalova J, Gazak R, Hrbac J, Sedmera P, Kren V, Lazzaroni R, Duroux JL, Walterova D (2008) Mechanism of the antioxidant action of silybin and 2,3-dehydrosilybin flavonolignans: a joint experimental and theoretical study. J Phys Chem A 112(5):1054–1063. https://doi.org/10.1021/jp075814h CrossRefGoogle Scholar
- 9.Lirussi F, Beccarello A, Zanette G, De Monte A, Donadon V, Velussi M, Crepaldi G (2002) Silybin-beta-cyclodextrin in the treatment of patients with diabetes mellitus and alcoholic liver disease. Efficacy study of a new preparation of an anti-oxidant agent. Diabetes Nutr Metab 15(4):222–231Google Scholar
- 10.Huseini HF, Larijani B, Heshmat R, Fakhrzadeh H, Radjabipour B, Toliat T, Raza M (2006) The efficacy of Silybum marianum (L.) Gaertn. (silymarin) in the treatment of type II diabetes: a randomized, double-blind, placebo-controlled, clinical trial. Phytother Res 20(12):1036–1039. https://doi.org/10.1002/ptr.1988 CrossRefGoogle Scholar
- 11.Federico A, Trappoliere M, Tuccillo C, de Sio I, Di Leva A, Del Vecchio Blanco C, Loguercio C (2006) A new silybin-vitamin E-phospholipid complex improves insulin resistance and liver damage in patients with non-alcoholic fatty liver disease: preliminary observations. Gut 55(6):901–902. https://doi.org/10.1136/gut.2006.091967 CrossRefGoogle Scholar
© Società Italiana di Medicina Interna 2018